Faich G A
Pharmacotherapy. 1987 Jan-Feb;7(1):25-7. doi: 10.1002/j.1875-9114.1987.tb03502.x.
In 1984 an extensive review of phenylbutazone risks was undertaken by the Food and Drug Administration (FDA). Since that review, new recommendations for the drug's use have been published. Marketed in 1952, phenylbutazone has long been recognized as capable of inducing aplastic anemia. The risk of marrow depression is greatest in elderly females treated for over a month. Overall, the risk does not exceed that of many commonly used drugs (e.g., penicillin, which induces anaphylaxis). Nonetheless, phenylbutazone should not be a drug of first choice and should not be used for minor, self-limited conditions.
1984年，美国食品药品监督管理局（FDA）对保泰松的风险进行了全面审查。自那次审查以来，已发布了该药物使用的新建议。保泰松于1952年上市，长期以来一直被认为能够诱发再生障碍性贫血。接受治疗超过一个月的老年女性发生骨髓抑制的风险最大。总体而言，该风险不超过许多常用药物（如诱发过敏反应的青霉素）的风险。尽管如此，保泰松不应作为首选药物，也不应用于轻微的自限性疾病。
